Nesiritide: complete guide

Nesiritide is recombinant human B-type natriuretic peptide, approved by FDA as Natrecor in 2001 and now discontinued. This guide covers its structure, mechanism, trials and warnings.

Complete guide5 min read

Key takeaway

FDA approved nesiritide as Natrecor on August 10, 2001. It has a molecular weight of 3,464 g/mol. In the large ASCEND-HF trial of 7,141 patients, it did not significantly reduce heart failure rehospitalization or death at 30 days. Drugs@FDA now lists Natrecor as discontinued, and FDA has determined it was not withdrawn for safety or effectiveness reasons.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Natrecor on August 10, 2001.” (this article)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited2 in this article · 2 across 1 article on Nesiritide
Related productsResearch peptide catalog

Nesiritide is a recombinant copy of human B-type natriuretic peptide (BNP), a 32-amino-acid hormone made by the heart’s ventricles. It was approved as Natrecor for acutely decompensated heart failure and is no longer marketed in the United States. This guide covers its structure, mechanism, labeled use, key trials and warnings. Sources were checked on November 17, 2026.

Quick answer: Nesiritide is a recombinant natriuretic peptide that relaxes blood vessels. Its label covered acutely decompensated heart failure with shortness of breath at rest or with minimal activity. The label had no boxed warning. Its warnings were low blood pressure, worsening kidney function and allergic reactions.

Vitrapep does not sell nesiritide; this page is a reference summary of published research and regulatory information.

What is nesiritide?

The Natrecor label calls it “a sterile, purified preparation of human B-type natriuretic peptide (hBNP).” It is “manufactured from E. coli using recombinant DNA technology.” It “has the same 32 amino acid sequence as the endogenous peptide, which is produced by the ventricular myocardium” (Natrecor label, 2019). The ventricular myocardium is the muscle of the heart’s main pumping chambers.

PubChem lists the formula as C143H244N50O42S4 and the molecular weight as 3,464.0 g/mol, matching the label (PubChem CID 71308561). ChEBI text in PubChem simply says, “Nesiritide is a polypeptide.” BNP belongs to the natriuretic peptide family, as does C-type natriuretic peptide, the template for vosoritide (Voxzogo label, 2024). Our peptide hormones guide covers the wider group.

Drugs@FDA lists the original approval of Natrecor (NDA 020920) on August 10, 2001, to Scios (Drugs@FDA). The last label posted there is dated January 2019.

Table 1

Nesiritide: key facts

Fact Detail
Structure type Recombinant 32-amino-acid peptide, same sequence as human BNP; made in E. coli
Class Natriuretic peptide (vasodilator)
Molecular formula C143H244N50O42S4
Molecular weight 3,464.0 g/mol
First FDA approval August 10, 2001 (Natrecor, NDA 020920)
Brand names (US) Natrecor (Scios); listed as discontinued

How does nesiritide work?

The label explains that the heart releases BNP “in response to stretch.” Elevated BNP levels are associated with advanced heart failure and are “considered to be a compensatory mechanism in this disease.”

BNP “binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells.” That raises levels of a messenger molecule called cyclic GMP (cGMP). The label adds that cyclic GMP “serves as a second messenger to dilate veins and arteries” (Natrecor label, 2019). In lab tests on isolated human artery and vein tissue, nesiritide relaxed vessels that had been made to contract.

In plain terms, nesiritide widens blood vessels. In trials, its main measured effect was a drop in pulmonary capillary wedge pressure (PCWP). PCWP is a pressure reading taken with a heart catheter.

What is nesiritide approved for?

The 2019 Natrecor label covers “the treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity.” Dyspnea means shortness of breath.

The label adds: “In this population, the use of NATRECOR reduced pulmonary capillary wedge pressure and improved short term (3 hours) symptoms of dyspnea.” The product is no longer marketed, so this describes the last approved label rather than current practice.

What did the key trials show?

VMAC. This randomized, double-blind human trial enrolled 489 inpatients with shortness of breath at rest from decompensated heart failure. It compared nesiritide, nitroglycerin and placebo, each added to usual care. At 3 hours, wedge pressure fell by 5.8 mm Hg with nesiritide versus 2 mm Hg with placebo (P < .001). Patients on nesiritide also reported better breathing than with placebo (P = .03) (VMAC Investigators, 2002).

ASCEND-HF. This much larger randomized, placebo-controlled trial enrolled 7,141 patients hospitalized with acute heart failure. One co-primary end point was heart failure rehospitalization or death within 30 days. It occurred in 9.4% on nesiritide and 10.1% on placebo (P = 0.31). Gains in breathlessness at 6 and 24 hours were small and missed the trial’s preset bar for significance.

Worsening kidney function occurred in 31.4% versus 29.5% (P = 0.11). Hypotension was more common with nesiritide (O’Connor et al., 2011). The registry record is NCT00475852. The label reports 180-day deaths of 12.3% versus 12.7%, with no significant difference.

What side effects does the label list?

The Natrecor label has no boxed warning. It states that “the most common adverse reactions (≥3%) are hypotension, headache, nausea, and back pain.” First-day rates in the longer trials, excluding ASCEND-HF, Natrecor versus placebo:

  • Hypotension (low blood pressure): 12% versus 4%
  • Headache: 7% versus 6%
  • Nausea: 3% versus 1%
  • Back pain: 3% versus 1%

The label’s three warnings cover hypotension, worsening of renal function and hypersensitivity. In ASCEND-HF, symptomatic hypotension occurred in 7.1% of Natrecor patients and 4.0% of placebo patients. The label notes that serious allergic reactions are more likely in people sensitive to other recombinant peptides (Natrecor label, 2019).

What is nesiritide’s regulatory status, and how is it used in research?

Drugs@FDA lists Natrecor’s marketing status as discontinued. DailyMed’s labeling service returned no current nesiritide labels when we checked. A January 8, 2021, notice lists Natrecor among products FDA found “not withdrawn from sale for reasons of safety or effectiveness” (Federal Register, 2021).

That determination means FDA would not start steps to withdraw approval of generic versions that refer to Natrecor. The original approval itself was not withdrawn. The research summarized here is clinical, in human patients, plus the label’s isolated-tissue tests. We found no documented role as a routine laboratory reagent in the sources we checked.

Frequently asked questions about nesiritide

Is nesiritide a peptide?

Yes. It is a 32-amino-acid peptide with the same sequence as human B-type natriuretic peptide.

When was nesiritide approved?

Drugs@FDA lists the original approval of Natrecor on August 10, 2001.

Is Natrecor still sold in the United States?

Drugs@FDA lists it as discontinued. FDA has determined it was not withdrawn for safety or effectiveness reasons.

Did nesiritide reduce deaths in heart failure?

No significant reduction was shown. In ASCEND-HF, deaths and rehospitalizations at 30 days were similar to placebo, and 180-day deaths were 12.3% versus 12.7%.

Why does the body make BNP?

The label says the heart releases BNP in response to stretch. Levels rise in advanced heart failure and are considered a compensatory response.

What to know now

  • Structure: recombinant 32-amino-acid human BNP; C143H244N50O42S4; 3,464 g/mol.
  • Approval: Natrecor, August 10, 2001; now listed as discontinued.
  • Mechanism: raises cGMP in vessel walls, dilating veins and arteries.
  • Evidence: lowered wedge pressure at 3 hours in VMAC; no significant outcome benefit in ASCEND-HF.
  • Safety: no boxed warning; hypotension is the most common reaction.
  • Status: FDA found it was not withdrawn for safety or effectiveness reasons.

What we’re watching

Any new nesiritide label on DailyMed, including generic versions that refer to Natrecor. Related guides: vosoritide, angiotensin II and vasopressin.

More for heart & vessels

All 13 compounds for heart & vessels

Sources: Scios LLC 2019, NATRECOR (nesiritide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 020920 (NATRECOR) . Retrieved November 17, Drugs@FDA: NDA 020920 (NATRECOR); National Center for Biotechnology Information 2026, PubChem compound summary for CID 71308561, nesiritide; Publication Committee for the VMAC Investigators 2002, JAMA, 287; O’Connor 2011, The New England Journal of Medicine, 365; Scios 2007; U.S. Food and Drug Administration 2021, Federal Register, 86; BioMarin Pharmaceutical Inc 2024, VOXZOGO (vosoritide) prescribing information. All 8 citations

Back to the research library

References

  1. Scios LLC. (2019). NATRECOR (nesiritide) prescribing information (revised 01/2019). Drugs@FDA, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020920s036lbl.pdf
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 020920 (NATRECOR). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020920
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 71308561, nesiritide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/71308561
  4. Publication Committee for the VMAC Investigators. (2002). Nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA, 287(12), 1531-1540. https://doi.org/10.1001/jama.287.12.1531
  5. O’Connor, C. M., et al. (2011). Effect of nesiritide in patients with acute decompensated heart failure. The New England Journal of Medicine, 365(1), 32-43. https://doi.org/10.1056/NEJMoa1100171
  6. Scios, Inc. (2007). A study testing the effectiveness of nesiritide in patients with acute decompensated heart failure (ClinicalTrials.gov ID NCT00475852). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00475852
  7. U.S. Food and Drug Administration. (2021, January 8). Determination that ARALEN (chloroquine phosphate) ... and other drug products were not withdrawn from sale for reasons of safety or effectiveness. Federal Register, 86(5), 1516-1517. https://www.govinfo.gov/content/pkg/FR-2021-01-08/html/2021-00118.htm
  8. BioMarin Pharmaceutical Inc. (2024). VOXZOGO (vosoritide) prescribing information (revised 11/2024). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=228e8560-04a4-4bb1-a81f-29531a9e4d27